Skip to main content
SpringerLink
Log in

Pro re nata anti-VEGF treatment in pachychoroid neovasculopathy compared with age-related macular degeneration based on optical coherence tomography

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare anti-vascular endothelial growth factor (anti-VEGF) treatment in pachychoroid neovasculopathy (PNV) and age related macular degeneration (AMD).

Methods

Cases having pro re nata (PRN) anti-VEGF treatment for choroidal neovascularization were reviewed and grouped as PNV and AMD. Groups were compared according to central foveal thickness (CFT), best corrected visual acuity (BCVA), and total injection over 12 months. The correlation of beginning choroidal thickness, CFT, and BCVA with final BCVA was analyzed.

Results

Forty-seven PNV and 65 AMD cases were reviewed. Both the PNV group (p = 0.0001) and the AMD group (p = 0.003) had a significant improvement in BCVA and a significant decrease in CFT (p = 0.0001). However, BCVA was better at the 3-, 6-, and 12-month follow-up in PNV (p = 0.003, 0.002, 0.02). No significant CFT difference was observed between groups. The total number of injections was 5.7 ± 1.7 for PNV and 5.2 ± 1.5 for AMD (p = 0.09). Beginning BCVA was positively correlated with final BCVA in both groups.

Conclusion

The PRN treatment regimen was effective for PNV and AMD in terms of visual and anatomical outcomes. Visual response was better in PNV with PRN treatment with the same number of injections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659–1672. https://doi.org/10.1097/IAE.0b013e3182953df4

    Article  PubMed  Google Scholar 

  2. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB (2016) En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 36:499–516. https://doi.org/10.1097/IAE.0000000000000742

    Article  PubMed  Google Scholar 

  3. Spaide RF, Gemmy Cheung CM, Matsumoto H et al (2021) Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 86:100973. https://doi.org/10.1016/j.preteyeres.2021.100973

    Article  CAS  PubMed  Google Scholar 

  4. Sharma A, Parachuri N, Kumar N et al (2021) Vortex vein anastomosis and pachychoroid-an evolving understanding. Eye 35:1545–1547. https://doi.org/10.1038/s41433-021-01423-2

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ersoz MG, Arf S, Hocaoglu M et al (2018) Indocyanıne green angiography of pachychoroid pigment epitheliopathy. Retina 38:1668–1674. https://doi.org/10.1097/IAE.0000000000001773

    Article  PubMed  Google Scholar 

  6. Matsumoto H, Hoshino J, Mukai R et al (2021) Chronic choriocapillaris ischemia in dilated vortex vein region in pachychoroid neovasculopathy. Sci Rep 11:16274. https://doi.org/10.1038/s41598-021-95904-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9. https://doi.org/10.1097/IAE.0000000000000331

    Article  CAS  PubMed  Google Scholar 

  8. Yanagi Y (2020) Pachychoroid disease: a new perspective on exudative maculopathy. Jpn J Ophthalmol 64:323–337. https://doi.org/10.1007/s10384-020-00740-5

    Article  PubMed  Google Scholar 

  9. Miyake M, Ooto S, Yamashiro K et al (2015) Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5:16204. https://doi.org/10.1038/srep16204. (PMID: 26542071)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Baek J, Kook L, Lee WK (2019) Choriocapillaris flow impairments in association with pachyvessel in early stages of pachychoroid. Sci Rep 9:5565. https://doi.org/10.1038/s41598-019-42052-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146:496–500. https://doi.org/10.1016/j.ajo.2008.05.032

    Article  PubMed  Google Scholar 

  12. Dansingani KK, Perlee LT, Hamon S et al (2016) Risk alleles associated with neovascularization in a pachychoroid phenotype. Ophthalmology 123:2628–2630. https://doi.org/10.1016/j.ophtha.2016.06.060

    Article  PubMed  Google Scholar 

  13. Elfandi S, Ooto S, Miyata M et al (2021) Effects of intravitreous aflibercept injection in pachychoroid neovasculopathy: comparison with typical neovascular age-related macular degeneration. Clin Ophthalmol 15:1539–1549. https://doi.org/10.2147/OPTH.S285257

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cho HJ, Jung SH, Cho S et al (2019) Intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. J Ocul Pharmacol Ther 35:174–181. https://doi.org/10.1089/jop.2018.0107

    Article  CAS  PubMed  Google Scholar 

  15. Yoon J, Yoon W, Na SK et al (2021) Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci Rep 11:12052. https://doi.org/10.1038/s41598-021-91589-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Matsumoto H, Hiroe T, Morimoto M et al (2018) Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62:144–150. https://doi.org/10.1007/s10384-018-0562-0

    Article  CAS  PubMed  Google Scholar 

  17. Li X, Zhu Q, Egger A, Chang L, Wolf S, Song Y et al (2021) Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. Acta Ophthalmol 99:e336–345. https://doi.org/10.1038/s41598-019-38504-y

    Article  CAS  PubMed  Google Scholar 

  18. Hatz K, Prünte C (2017) Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. Acta Ophthalmol 95:e67–e72. https://doi.org/10.1111/aos.13031

    Article  CAS  PubMed  Google Scholar 

  19. Lee JH, Lee WK (2016) One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. Retina 36:889–895. https://doi.org/10.1097/IAE.0000000000000809

    Article  CAS  PubMed  Google Scholar 

  20. Guymer RH, Markey CM, McAllister IL et al (2019) Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology 126:723–734. https://doi.org/10.1016/j.ophtha.2018.11.025

    Article  PubMed  Google Scholar 

  21. Sadda S, Holekamp NM, Sarraf D et al (2022) Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis. Graefes Arch Clin Exp Ophthalmol 260:3781–378. https://doi.org/10.1007/s00417-022-05716-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Li E, Donati S, Lindsley KB et al (2020) Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 5(5):CD012208. https://doi.org/10.1002/14651858.CD005139.pub4

    PubMed  Google Scholar 

  23. Jung BJ, Kim JY, Lee JH et al (2019) Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep 9:1–7. https://doi.org/10.1038/s41598-019-38504-y

    Google Scholar 

  24. Martin DF, Maguire MG, Fine SL et al (2012) Comparison of Age-Related Macular Degeneration Treatments Trial (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398. https://doi.org/10.1016/j.ophtha.2012.03.053

    Article  PubMed  Google Scholar 

  25. Solomon SD, Lindsley KB, Krzystolik MG et al (2016) Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane systematic review. Ophthalmology 123:70–77.e1. https://doi.org/10.1002/14651858.CD005139.pub4

    Article  PubMed  Google Scholar 

  26. Selid PD, Jundt MC, Fortney AC, Beal JR (2014) Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 45:275–281. https://doi.org/10.3928/23258160-20140709-03

    Article  PubMed  Google Scholar 

  27. Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.006

    Article  PubMed  Google Scholar 

  28. Rao P, Lum F, Wood K et al (2018) Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology 125:522–528. https://doi.org/10.1016/j.ophtha.2017.10.010

    Article  PubMed  Google Scholar 

  29. Koizumi H, Kano M, Yamamoto A et al (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration.: Twelve-Month Results. Ophthalmology 123:617–624. https://doi.org/10.1016/j.ophtha.2015.10.039

    Article  PubMed  Google Scholar 

  30. Lee WK, Baek J, Dansingani KK et al (2016) Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina 36(Suppl 1):S73–S82. https://doi.org/10.1097/IAE.0000000000001346

    Article  PubMed  Google Scholar 

  31. Demirel S, Yanık Ö, Nalcı H et al (2017) The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography. Graefes Arch Clin Exp Ophthalmol 255:2317–2324. https://doi.org/10.1007/s00417-017-3793-8

    Article  PubMed  Google Scholar 

  32. Cheung CMG, Lai TYY, Teo K et al (2021) Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology 128:443–452. https://doi.org/10.1016/j.ophtha.2020.08.006

    Article  PubMed  Google Scholar 

  33. Chaikitmongkol V, Kong J, Khunsongkiet P et al (2019) Sensitivity and Specificity of Potential Diagnostic Features Detected Using Fundus Photography, Optical Coherence Tomography, and Fluorescein Angiography for Polypoidal Choroidal Vasculopathy. JAMA Ophthalmol 137(6):661–667. https://doi.org/10.1001/jamaophthalmol.2019.0565

    Article  PubMed  PubMed Central  Google Scholar 

  34. Liu R, Li J, Li Z et al (2016) Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography. Retina 36(4):778–786. https://doi.org/10.1097/IAE.0000000000000794

    Article  PubMed  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Ankara Training and Research Hospital, University of Health Sciences, Hacettepe Mh. Ulucanlar Cd. No: 89, 06230, Altındağ, Ankara, Turkey

    Güner Üney, Dicle Hazırolan, Nurten Ünlü & Özlem Candan

Authors
  1. Güner Üney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dicle Hazırolan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nurten Ünlü
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Özlem Candan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by GÜ, DH, NÜ, and ÖC. The first draft of the manuscript was written by GÜ and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Conceptualization: GÜ, DH; Methodology: GÜ; Formal analysis and investigation: GÜ; Writing-original draft preparation: GÜ, ÖC, NÜ; Writing-review and editing: GÜ, NÜ; Resources: ÖC; Supervision: NÜ.

Corresponding author

Correspondence to Güner Üney.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Health Sciences, Ankara Training and Research Hospital (Date 11.10.2023, No. E-23-1382).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Üney, G., Hazırolan, D., Ünlü, N. et al. Pro re nata anti-VEGF treatment in pachychoroid neovasculopathy compared with age-related macular degeneration based on optical coherence tomography. Int Ophthalmol 44, 164 (2024). https://doi.org/10.1007/s10792-024-03094-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10792-024-03094-w

Keywords

Search

Navigation